Neurotrope, Inc., a company focused on developing drugs to treat neurodegenerative diseases including Alzheimer's disease, announced that it has appointed its chief scientific officer, Dr. Daniel Alkon, to the additional role of president.
After approximately 30 years directing programmes on the molecular basis of associative memory at the National Neurologic Institute of NIH, and another approximately 15 years as the founding scientific director of the Blanchette Rockefeller Neurosciences Institute, Dr. Alkon has now decided to devote much more of his time to the development of drugs to treat neurodegeneration at Neurotrope.
Dr. Alkon stated, it has been a great honor and opportunity to have been a part of the Blanchette Rockefeller Neurosciences Institute and to oversee its discoveries of synaptic regeneration to treat the progression of diseases such as Alzheimer's disease, Fragile X, and Traumatic Brain Injury. Now, I believe it is crucial that I assume a more important and direct role at Neurotrope. I believe that Neurotrope's lead drug candidate, now in phase 2 trials across the nation, has the potential to treat and even possibly reverse the ravages of neurodegeneration and I want to be totally involved in the process to make that happen. I believe this is a very exciting time to be involved with the company."